Kachnic, Lisa A <br/><br/>
FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.  [electronic resource] 

 -  Cancer letters  Jun 2011 
 - 86-93 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2011.02.030  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Cell Line<br/>DNA Breaks, Double-Stranded--drug effects<br/>DNA Repair--drug effects<br/>DNA Topoisomerases, Type II--metabolism<br/>Drug Resistance, Neoplasm--physiology<br/>Etoposide--pharmacology<br/>Fanconi Anemia Complementation Group A Protein--metabolism<br/>Fanconi Anemia Complementation Group D2 Protein--metabolism<br/>Fluorescent Antibody Technique<br/>Humans<br/>RNA Interference<br/>Signal Transduction--drug effects<br/>Topoisomerase II Inhibitors--pharmacology